Author:
Berchem Guy,Peters Solange
Publisher
Springer International Publishing
Reference192 articles.
1. Stewart BW, Wild C, International Agency for Research on Cancer, World Health Organization. World cancer report 2014. Lyon/Geneva: International Agency for Research on Cancer WHO Press; 2014. xiv, 630 p.
2. Tang WF, Ye HY, Tang X, Su JW, Xu KM, Zhong WZ, et al. Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: a new milestone. Front Oncol. 2023;13:1063183.
3. Morgensztern D, Du L, Waqar SN, Patel A, Samson P, Devarakonda S, et al. Adjuvant chemotherapy for patients with T2N0M0 NSCLC. J Thorac Oncol. 2016;11(10):1729–35.
4. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.
5. Wakelee HA, Altorki NK, Zhou C, Csőszi T, Vynnychenko IO, Goloborodko O, et al. IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(15_suppl):8500.